Drugs inhibiting IL-1, P2X7R, and caspase-1 have been developed, although to date only IL-1 inhibitors have been successful in clinical studies of rheumatoid arthritis (RA) and cryopyrin-associated periodic syndrome (CAPS). Here, NLRP3 is linked to rheumatoid arthritis.